Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers-Reference-Cited by-同舟云学术

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers

Published:2024-03-25 Issue:7 Volume:5 Page:1121-1129
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Muquith Maishara,Espinoza Magdalena,Elliott Andrew,Xiu Joanne,Seeber Andreas,El-Deiry Wafik^ORCID,Antonarakis Emmanuel S.,Graff Stephanie L.,Hall Michael J.,Borghaei Hossein^ORCID,Hoon Dave S. B.,Liu Stephen V.,Ma Patrick C.,McKay Rana R.^ORCID,Wise-Draper Trisha,Marshall John,Sledge George W.,Spetzler David,Zhu Hao^ORCID,Hsiehchen David^ORCID

Funder

Cancer Prevention and Research Institute of Texas

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s43018-024-00752-x.pdf

Reference48 articles.

1. Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223–249 (2021).

2. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).

3. Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 12, 738 (2020).

4. Lei, Y., Li, X., Huang, Q., Zheng, X. & Liu, M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front. Oncol. 11, 617335 (2021).

5. Wang, D. R., Wu, X. L. & Sun, Y. L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target. Ther. 7, 331 (2022).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?;Current Oncology Reports;2024-07-30

2. Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence;2024-03-02